Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
about
Different treatment strategies and molecular features between right-sided and left-sided colon cancersCombination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cellsDNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancerAnalyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age.Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patientsColorectal cancer in Chinese patients: current and emerging treatment options.BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patientsPIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal CancerMutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer.Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.Prognostic impact of mutation profiling in patients with stage II and III colon cancerMutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancerAnti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by ComprehenMutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis.Mutations of key driver genes in colorectal cancer progression and metastasis.Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study.Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma.Upregulation of c-mesenchymal epithelial transition expression and RAS mutations are associated with late lung metastasis and poor prognosis in colorectal carcinoma.Mutation Status and Immunohistochemical Correlation of , and in 260 Chinese Colorectal and Gastric Cancers
P2860
Q26865322-B1771693-2149-456E-AFBC-B66C9732AFA2Q28539177-DB34C201-2E87-476C-9657-43C111C7AEBBQ33679684-89871045-803D-4651-9D40-15C04AF223D0Q33732199-94B71C27-E28B-4412-B075-1F3CD223B05DQ33775336-C53EED63-7C3D-446F-AD03-74E71361F87CQ33861210-0D65D453-41CA-4427-AC75-2224F288809FQ34352595-EA913029-569D-40EB-8EED-E146E159D579Q34517338-A0C83F70-3F4E-465A-A57C-DA12B0D1C412Q35045790-72D1FD91-F270-4DD8-9E99-58C14D0D2AC8Q35815544-51CE0A55-C1B1-4B29-B670-8CEA1C9728C9Q35944622-41975716-2C5A-40ED-96DB-806D9BD8436DQ36228558-44EB6A2A-D698-4714-BF73-A44EFA90046CQ36393095-DC9BF103-1CD2-48A4-8312-58541FE1D9AAQ36796320-539B2BDD-C3A9-4FED-9CBB-52B12FED39DCQ37317549-1566C6B5-B360-4EFA-8B62-FB8EF452D9B6Q37525272-9782F3AD-37F6-45BC-AA75-8BB760152DCAQ37608405-7134B65F-25D0-4012-B709-40C2ED9B21C7Q38219290-EBF2206C-9361-47D0-A05A-5C12E361D50CQ42145086-1BB094A1-2F61-45C5-9893-DEC57517B5D2Q42316814-BF884E46-9C19-4DBC-975C-26AC23F3544FQ47109685-8878CA51-8B37-4286-A33F-25FD0D2E6A3AQ48072505-FBF776CC-E8F4-40F3-AE13-E57C048185ABQ50097873-59DCFD5A-82C9-461E-AA7A-B0C35FF6E6EEQ52582055-9384EE53-4892-48A3-AD72-09278F96B5B1Q54949200-197BE703-4D65-4851-A7E0-D7FBF48350BEQ55028937-24B13DD9-400E-4FCA-A9AF-EAD2A546DF09Q55408333-0102507B-43CB-4DA6-BA61-F602A209072DQ58707595-90337476-F7DB-40D1-9AD6-9E67765F216B
P2860
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Effectors of epidermal growth ...... ics and personalized medicine.
@ast
Effectors of epidermal growth ...... ics and personalized medicine.
@en
type
label
Effectors of epidermal growth ...... ics and personalized medicine.
@ast
Effectors of epidermal growth ...... ics and personalized medicine.
@en
prefLabel
Effectors of epidermal growth ...... ics and personalized medicine.
@ast
Effectors of epidermal growth ...... ics and personalized medicine.
@en
P2093
P2860
P1433
P1476
Effectors of epidermal growth ...... ics and personalized medicine.
@en
P2093
Dongmei Lin
Hongying Yang
Jianfei Wang
Shuai Wang
Xiaohong Han
Yinchen Shen
Yuankai Shi
P2860
P304
P356
10.1371/JOURNAL.PONE.0081628
P407
P577
2013-12-10T00:00:00Z